Regarding the staging of patients with a PSA rise after primary treatment, a 2023 study by Burgard et al. evaluated the real-world efficacy of PSMA-PET in detecting tumor localization after early (PSA level ≤ 0.2 ng/mL) BCR [81]. The gene discussed is KLK3; the disease is neoplasm.